TOLLIP-mediated Autophagic Degradation Pathway Links the VCP-TMEM63A-DERL1 Signaling Axis to Triple-negative Breast Cancer Progression
Overview
Authors
Affiliations
Triple-negative breast cancer (TNBC) is the most challenging breast cancer subtype to treat due to the lack of effective targeted therapies. Transmembrane (TMEM) proteins represent attractive drug targets for cancer therapy, but biological functions of most members of the TMEM family remain unknown. Here, we report for the first time that TMEM63A (transmembrane protein 63A), a poorly characterized TMEM protein with unknown functions in human cancer, functions as a novel oncogene to promote TNBC cell proliferation, migration, and invasion and xenograft tumor growth and lung metastasis . Mechanistic investigations revealed that TMEM63A localizes in endoplasmic reticulum (ER) and lysosome membranes, and interacts with VCP (valosin-containing protein) and its cofactor DERL1 (derlin 1). Furthermore, TMEM63A undergoes autophagy receptor TOLLIP-mediated autophagic degradation and is stabilized by VCP through blocking its lysosomal degradation. Strikingly, TMEM63A in turn stabilizes oncoprotein DERL1 through preventing TOLLIP-mediated autophagic degradation. Notably, pharmacological inhibition of VCP by CB-5083 or knockdown of DERL1 partially abolishes the oncogenic effects of TMEM63A on TNBC progression both and . Collectively, these findings uncover a previously unknown functional and mechanistic role for TMEM63A in TNBC progression and provide a new clue for targeting TMEM63A-driven TNBC tumors by using a VCP inhibitor. ATG16L1, autophagy related 16 like 1; ATG5, autophagy related 5; ATP5F1B/ATP5B, ATP synthase F1 subunit beta; Baf-A1, bafilomycin A; CALCOCO2/NDP52, calcium binding and coiled-coil domain 2; CANX, calnexin; DERL1, derlin 1; EGFR, epidermal growth factor receptor; ER, endoplasmic reticulum; ERAD, endoplasmic reticulum-associated degradation; HSPA8, heat shock protein family A (Hsp70) member 8; IP, immunoprecipitation; LAMP2A, lysosomal associated membrane protein 2; NBR1, NBR1 autophagy cargo receptor; OPTN, optineurin; RT-qPCR, reverse transcription-quantitative PCR; SQSTM1/p62, sequestosome 1; TAX1BP1, Tax1 binding protein 1; TMEM63A, transmembrane protein 63A; TNBC, triple-negative breast cancer; TOLLIP, toll interacting protein; VCP, valosin containing protein.
Xu H, Yang S, Liu P, Zhang Y, Zhang T, Lan J Biomed Rep. 2025; 22(4):63.
PMID: 39991002 PMC: 11843188. DOI: 10.3892/br.2025.1941.
Li J, He R, Dang Y, Huang Z, Xiong D, Zhang L World J Gastrointest Oncol. 2025; 17(2):92437.
PMID: 39958559 PMC: 11756017. DOI: 10.4251/wjgo.v17.i2.92437.
Overexpression of PLCG2 and TMEM38A inhibit tumor progression in clear cell renal cell carcinoma.
Zhao Y, Yang L, Bai X, Du L, Lai H, Liu Y Sci Rep. 2025; 15(1):3192.
PMID: 39863641 PMC: 11763014. DOI: 10.1038/s41598-025-86644-1.
Cheng C, Zha Q, Sun L, Cui T, Guo X, Xing C Signal Transduct Target Ther. 2025; 10(1):26.
PMID: 39848960 PMC: 11758394. DOI: 10.1038/s41392-024-02120-8.
Transcription Impairment of TMEM208 by ZBTB14 Suppresses Breast cancer Radiotherapy Resistance.
Li Y, Liang L J Mammary Gland Biol Neoplasia. 2024; 29(1):20.
PMID: 39692812 PMC: 11655580. DOI: 10.1007/s10911-024-09573-1.